所有标记为「GLP-1」的文章
在保险计划表示尚未准备好参与后，CMS 已无限期推迟了一项聚焦肥胖药物覆盖的 Medicare 试点项目。
诺和诺德正同时应对两起离职事件，包括 GLP-1 先驱 Lotte Bjerre Knudsen 的退休，以及一位肥胖领域领导者转投勃林格殷格翰。
A study announced by the 23andMe Research Institute identified genetic predictors tied to both GLP-1 weight-loss efficacy and side effects, highlighting a possible path toward more personalized obesity treatment.
Two phase 3 EVOKE(+) trials found that semaglutide did not slow clinical progression in Alzheimer’s disease, despite earlier signals that GLP-1 drugs might help.
Structure Therapeutics报告了其口服GLP-1受体激动剂的鼓舞人心的第2期结果，推进了注射剂减重和糖尿病药物的药丸形式替代品。
After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.
Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.
Eli Lilly launches a program to make it easier for employers to add GLP-1 weight loss and diabetes drugs to their health plans, addressing a major coverage gap.
Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.
With one in eight American adults now taking GLP-1 medications like Ozempic and Wegovy, researchers at Georgia State University have uncovered why patients regain weight after stopping treatment — and a potential combination therapy that could solve the problem by targeting the brain's stress response system.
